Haemonetics sells whole blood assets to GVS for $44.6M cash plus up to $22.5M earnout

HAEMONETICS CORP

Total consideration up to $67.1M: $44.6M cash at close plus up to $22.5M contingent on sales growth and milestones.
Assets sold include whole blood collection, processing, and filtration portfolio, plus Covina, CA manufacturing facility and Tijuana, Mexico equipment.
Haemonetics retains its apheresis line for automated blood collection (platelets, plasma, red cells).
Transaction expected to close in Q1 2025, subject to customary closing conditions.
GVS (not publicly traded) is a filter-solutions manufacturer in healthcare and life sciences.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.